Biovica International Ab Is A Biotech Company Based In Uppsalaswedenfocused On Developing And Commercializing Blood Based Biomarker Assays To Improve Cancer Treatment Monitoringtheir Flagship Productthe Divitum Tka Testmeasures Cell Proliferation In Solid Tumorsthis Assay Is Particularly Useful For Monitoring Disease Progression And Evaluating Treatment Efficacy In Patients Receiving Cdk4 6 Inhibitorsespecially In Metastatic Breast Cancer The Company Has A Strong Research Foundationhaving Conducted Studies Involving Over 4 500 Patients And Published 28 Scientific Papersbiovica Is Actively Engaged In 22 Pharmaceutical Projectsdemonstrating Its Commitment To Advancing Cancer Treatment Through Innovative Biomarkerstheir Products Are Aimed At Oncologists And Healthcare Providersoffering Valuable Insights For Treatment Decisions Based On Disease Progression And Therapy Response
